Your search for oral corticosteroids returned 3 results

Imbruvica is a first-in-class, oral Bruton’s tyrosine kinase (BTK) inhibitor.

Genentech announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

AstraZeneca announced that two pivotal Phase 3 registrational trials for benralizumab achieved their primary endpoint, demonstrating significant reductions in the annual asthma exacerbation rate compared to placebo.